Your institution may have access to this item. Find your institution then sign in to continue.
Title
Decitabine Receives US Orphan Drug Designation for AML.
Abstract
The article reports on the approval of the U.S. Food and Drug Administration (FDA) to the decitabine which was developed by MGI Pharma Inc. for the treatment of acute myeloid leukemia. Decitabine is a hypomethylating agent that produce its antineoplastic effects by incorporation into DNA and inhibition of the enzyme DNA methyltransferase. FDA granted decitabine an orphan drug designation because of its effectivity in treating rare diseases.